tiprankstipranks
Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
US Market

Immix Biopharma, Inc. (IMMX) Income Statement

98 Followers

Immix Biopharma, Inc. Income Statement

Last quarter (Q ), Immix Biopharma, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q, Immix Biopharma, Inc.'s net income was $-4.28M. See Immix Biopharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 1.93M$ 8.22M$ 1.35M$ 453.85K$ 842.50K
Operating Income
$ -9.52M$ -8.22M$ -1.35M$ -453.85K$ -842.50K
Net Non Operating Interest Income Expense
$ 343.43K$ -497.00$ -179.85K$ -101.98K$ -109.98K
Other Income Expense
--$ 22.85M$ -574.49K$ 224.00
Pretax Income
$ -14.22M$ -8.22M$ -24.38M$ -1.13M$ -952.26K
Tax Provision
$ 13.24K$ 10.27K$ 6.01K$ 17.55K$ 20.55K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -9.08M$ -8.23M$ -24.38M$ -1.15M$ -972.81K
Basic EPS
$ -0.92$ -0.59$ -6.64$ -0.06$ -0.12
Diluted EPS
$ -0.65$ -0.59$ -6.64$ -0.06$ -0.12
Basic Average Shares
$ 61.40M$ 13.89M$ 3.67M$ 8.44M$ 8.44M
Diluted Average Shares
$ 47.51M$ 13.89M$ 3.67M$ 8.44M$ 8.44M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 1.93M$ 8.22M$ 1.35M$ 453.85K$ 842.50K
Net Income From Continuing And Discontinued Operation
$ -14.15M$ -8.23M$ -24.38M$ -1.15M$ -972.81K
Normalized Income
$ -6.26M--$ -728.11K$ -972.81K
Interest Expense
---$ 101.98K$ 109.98K
EBIT
$ -14.22M$ -8.22M$ -24.20M$ -1.03M$ -842.27K
EBITDA
$ -14.21M$ -8.22M$ -24.14M$ -1.03M$ -841.19K
Currency in USD

Immix Biopharma, Inc. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis